- Home>
- Journal Watch
- >
- hypercholesterolemia
Search for hypercholesterolemia in all Journal Watch editions
Physician-authored summaries on the latest research on hypercholesterolemia, editorials on hypercholesterolemia, and perspectives on hypercholesterolemia - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 287 results - Relevance
- Date
You searched for: hypercholesterolemia
-
FDA Approves Drug for Homozygous Familial Hypercholesterolemia Free
- January 31, 2013
- Physician's First Watch
The FDA has approved mipomersen sodium (Kynamro) for patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering medications and diet. Mipomersen is... -
Eicosapentaenoic Acid Reduces Nonfatal Coronary Events in Hypercholesterolemia Free
- March 30, 2007
- Physician's First Watch
Consumption of the fish-oil component eicosapentaenoic acid (EPA) lowers rates of unstable angina and nonfatal coronary events in patients with hypercholesterolemia, researchers report in... -
Should Hypercholesterolemia Treatments Start Much Sooner in Life? Free
- October 18, 2012
- Physician's First Watch
Keeping LDL cholesterol low throughout life is more effective at preventing atherosclerotic disease than starting statins in middle age, a series of analyses in the... -
New Statin Approved for Hypercholesterolemia Free
- August 4, 2009
- Physician's First Watch
Pitavastatin (Livalo) has been approved for patients with elevated blood cholesterol levels, the FDA announced on Monday. The drug's base structure has a unique cyclopropyl... -
Red Yeast Rice for Hypercholesterolemia in People with Statin-Related Myalgias
This herbal supplement lowered LDL cholesterol levels without causing intolerable myalgias.- Reviewing:
- Becker DJ et al., Ann Intern Med 2009 Jun 16; 150:830.
-
A Hat Trick for a New Type of LDL-Lowering Agent
- January 2, 2013
- JoAnne M. Foody, MD
- Cardiology
In three separate phase II trials, a proprotein convertase subtilisin/kexin type 9 protease inhibitor achieves significant reductions in LDL levels compared with placebo or ezetimibe.- Reviewing:
- Koren MJ et al., Lancet 2012 Dec 8/14; 380:1995. Giugliano RP et al., Lancet 2012 Dec 8/14; 380:2007. Tonkin AM and Watts GF., Lancet 2012 Dec 8/14; 380:1971. Raal F et al., Circulation 2012 Nov 13; 126:2408.
-
You Snooze, You Win
- October 19, 2010
- Erik St. Louis, MD
- Neurology
A large, longitudinal cohort study demonstrated a convincing association between short sleep duration and hypercholesterolemia in young women.- Reviewing:
- Gangwisch JE et al., Sleep 2010 Jul 1; 33:956.
-
Vytorin Fails to Improve Carotid Intima–Media Thickness
- April 1, 2008
- Allan S. Brett, MD
- General Medicine
Despite lower LDL cholesterol levels with Vytorin, no clinical benefits were noted.
Audio Interview- Reviewing:
- Kastelein JJP et al., N Engl J Med 2008 Apr 3; 358:1504.
-
Does Ezetimibe ENHANCE the Benefits of Statins?
- March 30, 2008
- Harlan M. Krumholz, MD, SM
- Cardiology
Perhaps not, suggest these findings from a study of combination therapy’s effect on carotid-artery intima–media thickness- Reviewing:
- Kastelein JJP et al. for the ENHANCE investigators., N Engl J Med 2008 Apr 3; 358:1431. Brown BG and Taylor AJ., N Engl J Med 2008 Apr 3; 358:1504. Drazen JM et al., N Engl J Med 2008 Apr 3; 358:1507.
-
Policosanol: No Lipid-Lowering Effect
- June 8, 2006
- JoAnne M. Foody, MD
- Cardiology
This sugar cane derivative had no benefit, at any dose, in a randomized, placebo-controlled trial from Germany.- Reviewing:
- Berthold HK et al., JAMA 2006 May 17; 295:2262-9.
-
Four CV Risk Factors Predict Most of Peripheral Artery Disease Risk in Men Free
- October 24, 2012
- Physician's First Watch
Four common cardiovascular risk factors account for most of the risk for peripheral artery disease (PAD) in middle-aged and older men, according to a... -
How New-Onset Atrial Fibrillation Affects Survival in Healthy Women Free
- June 16, 2011
- Thomas L. Schwenk, MD
- General Medicine
Risk for premature death was elevated for both cardiovascular and noncardiovascular causes.
CME Exam- Reviewing:
- Conen D et al., JAMA 2011 May 25; 305:2080. Miyasaka Y and Tsang TSM., JAMA 2011 May 25; 305:2116.
-
A New Agent for Lowering Lipid Levels?
- March 10, 2010
- JoAnne M. Foody, MD
- Cardiology
In a phase II study, eprotirome, a thyromimetic, yielded promising results when added to statins in patients with treatment-resistant hypercholesterolemia.- Reviewing:
- Ladenson PW et al., N Engl J Med 2010 Mar 11; 362:906.
-
Childhood Obesity, Glucose Intolerance, and Hypertension Increase Risk for Premature Adult Mortality Free
- February 10, 2010
- F. Bruder Stapleton, MD
- Pediatrics and Adolescent Medicine
A possible association between childhood obesity and premature death might be partially mediated by childhood glucose intolerance and hypertension.- Reviewing:
- Franks PW et al., N Engl J Med 2010 Feb 11; 362:485.
-
Lipid Screening in Childhood — New Recommendations from the AAP
- July 30, 2008
- JoAnne M. Foody, MD
- Cardiology
Controversial new recommendations advocate wider screening and use of statins in children.- Reviewing:
- Daniels SR et al., Pediatrics 2008 Jul; 122:198.
-
Lipid Screening in Childhood — New Recommendations from the AAP Free
Controversial new recommendations advocate wider screening and use of statins in children.- Reviewing:
- Daniels SR et al., Pediatrics 2008 Jul; 122:198.
-
Questions Raised About Efficacy of Ezetimibe Free
- March 31, 2008
- Physician's First Watch
The widely used anti-cholesterol drug ezetimibe (marketed as Zetia and, in combination with simvastatin, as Vytorin) improved LDL cholesterol but not other disease markers... -
Learning the Lessons of ENHANCE Free
- March 30, 2008
- Cardiology
How negative trial findings can — and should — change practice -
Cholesterol Drug Shows No Benefit, Possible Harm Free
- January 15, 2008
- Physician's First Watch
Zetia (ezetimibe) doesn't slow the progression of arterial plaque but rather may increase plaque growth, according to results from the Enhance study. Merck/Schering-Plough... -
Statins' Preventive Effects Evident Years After Stopping Free
- October 11, 2007
- Physician's First Watch
Treatment with pravastatin for 5 years may lower the risk for coronary events for up to 10 additional years, according to a New England Journal...
Sort by:
Items 1 to 20 of 287 results - Relevance
- Date
